[go: up one dir, main page]

WO2002013847A3 - Methods for diagnosis and therapy of hematological and virus-associated malignancies - Google Patents

Methods for diagnosis and therapy of hematological and virus-associated malignancies Download PDF

Info

Publication number
WO2002013847A3
WO2002013847A3 PCT/US2001/025408 US0125408W WO0213847A3 WO 2002013847 A3 WO2002013847 A3 WO 2002013847A3 US 0125408 W US0125408 W US 0125408W WO 0213847 A3 WO0213847 A3 WO 0213847A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
methods
hematological
diagnosis
therapy
Prior art date
Application number
PCT/US2001/025408
Other languages
French (fr)
Other versions
WO2002013847A2 (en
Inventor
Alexander Gaiger
Martin A Cheever
Susan Hand-Zimmermann
Original Assignee
Corixa Corp
Alexander Gaiger
Martin A Cheever
Susan Hand-Zimmermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp, Alexander Gaiger, Martin A Cheever, Susan Hand-Zimmermann filed Critical Corixa Corp
Priority to AU2001283360A priority Critical patent/AU2001283360A1/en
Publication of WO2002013847A2 publication Critical patent/WO2002013847A2/en
Publication of WO2002013847A3 publication Critical patent/WO2002013847A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.
PCT/US2001/025408 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies WO2002013847A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001283360A AU2001283360A1 (en) 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63828000A 2000-08-14 2000-08-14
US09/638,280 2000-08-14
US67590400A 2000-09-28 2000-09-28
US09/675,904 2000-09-28

Publications (2)

Publication Number Publication Date
WO2002013847A2 WO2002013847A2 (en) 2002-02-21
WO2002013847A3 true WO2002013847A3 (en) 2002-12-19

Family

ID=27093044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025408 WO2002013847A2 (en) 2000-08-14 2001-08-13 Methods for diagnosis and therapy of hematological and virus-associated malignancies

Country Status (2)

Country Link
AU (1) AU2001283360A1 (en)
WO (1) WO2002013847A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2023078273A1 (en) 2021-11-03 2023-05-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation for an antibody-drug conjugate
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525787A (en) * 2003-01-03 2006-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Rhesus monkey HER2 / neu, nucleotide encoding the same and use thereof
EP3858387A1 (en) 2003-11-06 2021-08-04 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
RU2404810C9 (en) 2004-06-01 2015-06-20 Дженентек, Инк. Conjugates antibody-medicinal agent and methods
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
EP2662095A1 (en) 2010-04-15 2013-11-13 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
JP2013534520A (en) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド Cysteine engineered antibodies and conjugates
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CN103608684B (en) 2011-05-12 2016-05-04 基因泰克公司 A Multiple Reaction Monitoring LC-MS/MS Method for the Detection of Therapeutic Antibodies in Animal Samples Using Framework Signature Peptides
HUE025661T2 (en) 2011-10-14 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
SMT201900017T1 (en) 2012-10-12 2019-02-28 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK2906251T3 (en) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22-antibody conjugates
TR201808051T4 (en) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates.
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
DK2906253T3 (en) 2012-10-12 2018-10-22 Adc Therapeutics Sa Pyrrolobenzodiazepine anti-PSMA antibody conjugates
PT2766048E (en) 2012-10-12 2015-02-25 Spirogen Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES OF THE SAME
ES2731779T3 (en) 2013-03-13 2019-11-19 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
CN105307685B (en) 2013-03-13 2019-03-08 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016012410A2 (en) 2013-12-16 2017-09-26 Genentech Inc drug-antibody conjugate, drug-antibody conjugate, non-peptide compound, method of treating human disease and pharmaceutical composition
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112017003236A2 (en) 2014-09-12 2017-11-28 Genentech Inc cysteine engineered antibodies, drug conjugates and antibodies, drug and antibody conjugate preparation method and pharmaceutical composition
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EA201790359A1 (en) 2014-09-17 2017-08-31 Дженентек Инк. Pyrrolobenzodiazepines and their conjugates associated with disulfide binding to antibodies
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (en) 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
CN109476648B (en) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 Sevelamer antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (en) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
SI3612537T1 (en) 2017-04-18 2022-10-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20200129637A1 (en) 2017-04-20 2020-04-30 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (en) 2017-08-18 2021-06-30 메디뮨 리미티드 pyrrolobenzodiazepine conjugate
SG11202001907QA (en) 2017-09-20 2020-04-29 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (en) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (en) 2019-03-15 2024-05-06 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
CN110491450B (en) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 Tumor neogenesis antigen prediction platform and application thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0711565A1 (en) * 1994-11-10 1996-05-15 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
WO2001021192A2 (en) * 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROSSART PETER ET AL: "Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 96, no. 9, 1 November 2000 (2000-11-01), pages 3102 - 3108, XP002172006, ISSN: 0006-4971 *
BUHRING H-J ET AL: "THE RECEPTOR TYROSINE KINASE P185 HER2 IS EXPRESSED ON A SUBSET OF B-LYMPHOID BLASTS FROM PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND CHRONIC MYELOGENOUS LEUKEMIA", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 86, no. 5, 1 September 1995 (1995-09-01), pages 1916 - 1923, XP000560897, ISSN: 0006-4971 *
DISIS M L ET AL: "Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 156, no. 9, 1 May 1996 (1996-05-01), pages 3151 - 3158, XP002139506, ISSN: 0022-1767 *
GALY A ET AL: "Generation of immunogenic dendritic cells that are gene-modified to present the ERBB2 antigen.", IMMUNOLOGY, vol. 92, no. SUPPL. 1, December 1997 (1997-12-01), 5th Annual Congress of the British Society for Immunology;Brighton, England, UK; December 2-5, 1997, pages 12, XP001074064, ISSN: 0019-2805 *
IMAMURA N ET AL: "AGGRESSIVE DIFFUSE LYMPHOMA COEXPRESSING NRAS P21 AND C-ERBB-2 (NEU) ONCOGENE PRODUCTS, AND CALLA (CD10)", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 4, no. 5/6, 1991, pages 419 - 422, XP000560889, ISSN: 1042-8194 *
TIMMERMAN J M ET AL: "DENDRITIC CELL VACCINES FOR CANCER IMMUNOTHERAPY", ANNUAL REVIEW OF MEDICINE: SELECTED TOPICS IN THE CLINICAL SCIENCES, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 50, 1999, pages 507 - 529, XP001005422, ISSN: 0066-4219 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2023078273A1 (en) 2021-11-03 2023-05-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation for an antibody-drug conjugate
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Also Published As

Publication number Publication date
WO2002013847A2 (en) 2002-02-21
AU2001283360A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
WO2002013847A3 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001021192A3 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
EP1445317A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001249881A1 (en) Method of treating the heart
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003044053A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002044418A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2003008443A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ATE242238T1 (en) QUINOLINE AND QUINAZOLINE COMPOUNDS OF THERAPEUTIC UTILITY, PARTICULARLY FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA
ID21529A (en) METHODS AND COMPOSITIONS FOR TUMOR TREATMENT, PREVENTION, RELATIONSHIP RELATED TO TUMORS AND COCOEX
ZA200402319B (en) Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer.
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001251084A1 (en) Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
AU5947701A (en) Methods for identification, diagnosis, and treatment of breast cancer
AU2001240046A1 (en) Method of treating skin conditions
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
HUP0203197A3 (en) Use of docetaxel for treating hepatocellular carcinoma
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2002044419A3 (en) Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP